500 related articles for article (PubMed ID: 32302001)
1. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
3. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
4. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
5. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
7. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
8. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB; Røikjer JB; Dal J; Jensen MH
Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
[TBL] [Abstract][Full Text] [Related]
9. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
10. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.
Clark A; Mohammed AS; Raut A; Moore S; Houlden R; Awad S
Can J Diabetes; 2021 Apr; 45(3):214-219. PubMed ID: 33046401
[TBL] [Abstract][Full Text] [Related]
13. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
[TBL] [Abstract][Full Text] [Related]
14. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Chaudhry A; Roels C; Lee J
Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.
Cohen B; Harris YT; Schulman-Rosenbaum R
Endocr Pract; 2024 Apr; 30(4):402-408. PubMed ID: 38081453
[TBL] [Abstract][Full Text] [Related]
17. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
19. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence.
Mehta PB; Robinson A; Burkhardt D; Rushakoff RJ
Endocr Pract; 2022 Sep; 28(9):884-888. PubMed ID: 35753675
[TBL] [Abstract][Full Text] [Related]
20. Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence.
Thiruvenkatarajan V; Inglis JM; Meyer E; Umapathysivam MM; Nanjappa N; Van Wijk R; Jesudason D
Can J Diabetes; 2023 Apr; 47(3):287-291. PubMed ID: 36739255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
